At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MDGL Madrigal Pharmaceuticals
Post-Mkt 08-28 18:09:42 EDT
533.76
-9.93
-1.83%
盘后533.76
+0.000.00%
16:10 EDT
High542.16Low528.29Vol268.66K
Open539.38D1 Closing543.69Amplitude2.55%
Mkt Cap12.31BTradable Cap7.33BTotal Shares23.06M
T/O143.89MT/O Rate1.96%Tradable Shares13.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Can Madrigal Pharmaceuticals (MDGL) Still Offer Value After Its Big Run?
Simply Wall St.  ·  03:28
Can Madrigal Pharmaceuticals (MDGL) Still Offer Value After Its Big Run?
Movement Alert｜Madrigal Pharmaceuticals Rises 5.08% in Regular Trading, Trading at $537.92
Market Focus  ·  08-27 03:02
Movement Alert｜Madrigal Pharmaceuticals Rises 5.08% in Regular Trading, Trading at $537.92
Madrigal Grants 4,676 Inducement RSUs to 13 New Employees Under 2025 Plan
Reuters  ·  08-21
Madrigal Grants 4,676 Inducement RSUs to 13 New Employees Under 2025 Plan
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  08-21
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  08-21
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow
Simply Wall St.  ·  08-20
Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow
Madrigal Pharma Director John C. Reed Files Initial Beneficial Ownership Statement
Reuters  ·  08-19
Madrigal Pharma Director John C. Reed Files Initial Beneficial Ownership Statement
Madrigal Extends Resmetirom Into Pediatric MASH, Boosting Long-Term Upside for MDGL
TIPRANKS  ·  08-14
Madrigal Extends Resmetirom Into Pediatric MASH, Boosting Long-Term Upside for MDGL
Madrigal Pharmaceuticals Adds Renowned Leader to Board
TIPRANKS  ·  08-12
Madrigal Pharmaceuticals Adds Renowned Leader to Board
Madrigal Appoints J&J R&D Chief John Reed to Board
Reuters  ·  08-12
Madrigal Appoints J&J R&D Chief John Reed to Board
Madrigal Appoints John C. Reed, M.d., Ph.d., to Its Board of Directors
THOMSON REUTERS  ·  08-12
Madrigal Appoints John C. Reed, M.d., Ph.d., to Its Board of Directors
Press Release: Madrigal Appoints John C. Reed, M.D., Ph.D., to Its Board of Directors
Dow Jones  ·  08-12
Press Release: Madrigal Appoints John C. Reed, M.D., Ph.D., to Its Board of Directors
Madrigal Pharmaceuticals Grants 4,263 Inducement RSUs to 10 New Employees
Reuters  ·  08-07
Madrigal Pharmaceuticals Grants 4,263 Inducement RSUs to 10 New Employees
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  08-07
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals to Present at Canaccord Genuity Annual Growth Conference
Reuters  ·  08-06
Madrigal Pharmaceuticals to Present at Canaccord Genuity Annual Growth Conference
Arrowhead Pharmaceuticals Q3 Revenue Jumps on Redemplo Growth
Reuters  ·  08-05
Arrowhead Pharmaceuticals Q3 Revenue Jumps on Redemplo Growth
Madrigal upgraded to Outperform from Peer Perform at Wolfe Research
TIPRANKS  ·  08-04
Madrigal upgraded to Outperform from Peer Perform at Wolfe Research
Madrigal Pharmaceuticals is Maintained at Overweight by Barclays
Dow Jones  ·  08-03
Madrigal Pharmaceuticals is Maintained at Overweight by Barclays
Madrigal Pharmaceuticals price target lowered to $962 from $964 at Barclays
TIPRANKS  ·  08-03
Madrigal Pharmaceuticals price target lowered to $962 from $964 at Barclays
Movement Alert｜Madrigal Pharmaceuticals Falls 5.07% in Regular Trading, Q2 Earnings Loss Widening Extends Selling Pressure
Market Focus  ·  07-31
Movement Alert｜Madrigal Pharmaceuticals Falls 5.07% in Regular Trading, Q2 Earnings Loss Widening Extends Selling Pressure

Introduction

Company Name.
Madrigal Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.
Issue price:
--